Danaher Reports First Quarter 2025 Financial Results and Outlook

Details

Non-GAAP core revenue remained flat year-over-year. The company anticipates low-single-digit growth in non-GAAP core revenue for the second quarter and approximately 3% growth for the full year 2025. The company also provided full-year adjusted diluted net earnings per common share guidance in the range of $7.60 to $7.75.

Items reported

Exhibits (1)

About Danaher Corporation

Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.